Desogestrel and Severe Psychiatric Disorders: A Retrospective Analysis of Federal Adverse Event Reporting System and EudraVigilance.

Manan Shah, Charmy Kothari

Current drug safety 2021

filter terms:

Several studies have been published which stated that there is some connection between severe psychiatric disorders and contraceptive drug "desogestrel". However, nothing in the summary of product characteristics (SmPC) or patient information leaflets of desogestrel about anxiety, more severe anxiety leading to panic attacks, or about risks of severe depression leading to suicidal thoughts or suicide attempts. To examine the safety and risk association between hormonal contraceptive desogestrel among women with psychiatric disorders using adverse drug reaction database of FDA Adverse Events Reporting System (FAERS) and EudraVigilance (EV). Individual case safety reports (ICSRs) of only female patients from Jan 1999 to Nov 2019 and Jan 2004 to Nov 2019 were downloaded from FAERS and EV database, respectively. Reports of drug desogestrel, dienogest, norgestimate, cyproterone acetate and drospirenone were downloaded. Disproportionality method of data mining was used to calculate the risk association. The lower limit of 95% CI of PRR is -0.28 and 2.02, PRR is 1.08 and 9.18, ROR is 1.09 (95%CI: 0.74, 1.59) and 9.26 (95% CI: 7.21, 11.89), Chi square value is 1.21 and 433.68, and IC-2SD is -0.27 and 2.60, respectively for data obtained from FAERS and EV. From this study, we conclude that there is no new emerging signal for the drug-event pair studied. Further study and continuous monitoring are required in future to know more about this drug-event pair association, as severe psychiatric disorders are not yet mentioned or included in SmPC and patient leaflet of desogestrel. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Citation

Manan Shah, Charmy Kothari. Desogestrel and Severe Psychiatric Disorders: A Retrospective Analysis of Federal Adverse Event Reporting System and EudraVigilance. Current drug safety. 2021;16(3):278-283